Tue, 08 May 2012 20:05:21 GMT

About - News & IssuesFDA Panel Unanimously Rejects Regeneron's Arcalyst As Gout TreatmentWall Street JournalBy Jennifer Corbett Dooren Of DOW JONES NEWSWIRES WASHINGTON (Dow Jones)--A federal advisory panel unanimously rejected Regeneron Pharmaceuticals Inc.'s (REGN) Arcalyst has a proposed treatment for gout, saying current safety data was inadequate to ...Regeneron's Arcalyst As Gout Treatment Rejected By FDA PanelThe InquisitrRegeneron: FDA panel says no to Arcalyst for goutCBS NewsArthritis Advisory Committee Unanimously Against Arcalyst for GoutAbout - News & Issuesall 6 news articles »

Thu, 17 May 2012 20:16:17 GMT

Pharmos Corporation Announces Successful Completion Of Proof-of-concept ...MarketWatch (press release)This phase 2a trial was conducted at the Duke Clinical Research Unit of Duke University and the principal investigator was John Sundy, MD, PhD, an expert and key opinion leader in the treatment of gout. The trial was designed to assess the safety and ...Pharmos completes levotofisopam phase 2a trial on hyperuricemia, goutNews-Medical.netall 16 news articles »

Wed, 09 May 2012 12:31:49 GMT

French TribuneRegeneron Dips on Safety Concern Over Gout Treatment [UPDATE]Minyanville.comBy Brett Chase May 09, 2012 8:25 am FDA raises questions about whether Regeneron's drug Arcalyst's benefit to gout patients is worth the safety risk. UPDATE May 9, 2012 Regeneron's (REGN) drug Arcalyst shouldn't be approved for the treatment of gout ...Regeneron's Arcalyst Fails to Win Panel Backing for GoutBusinessWeekUS FDA committtee voted against approval of Regeneron's Arcalyst for gout ...pharmabiz.comFDA advisers rebuff Regeneron gout drugChicago TribuneMedPage Today -MarketWatch (press release)all 59 news articles »